Λίστα αντικειμένων
In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM) grafts, which may be associated with adverse outcomes. We compared outcomes of HCT in BM graft and PB graft recipients age ≥18 years with hematologic malignancies who underwent T cell- replete haploidentical HCT and received graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil.
Highlights
•The risk of steroid-refractory acute graft-versus-host disease (GVHD) was higher with peripheral blood (PB) grafts compared with bone marrow (BM) grafts for haploidentical hematopoietic cell transplantation (haplo-HCT).
•There was a greater risk of therapy-requiring chronic GVHD with PB grafts compared with BM grafts for haplo-HCT.
•There was a greater risk of infections with PB grafts versus BM grafts for haplo-HCT.
•The time to engraftment and duration of hospitalization were similar with BM grafts and PB grafts.
•Immune reconstitution was similar with BM grafts and PB grafts
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Highlights
•The risk of steroid-refractory acute graft-versus-host disease (GVHD) was higher with peripheral blood (PB) grafts compared with bone marrow (BM) grafts for haploidentical hematopoietic cell transplantation (haplo-HCT).
•There was a greater risk of therapy-requiring chronic GVHD with PB grafts compared with BM grafts for haplo-HCT.
•There was a greater risk of infections with PB grafts versus BM grafts for haplo-HCT.
•The time to engraftment and duration of hospitalization were similar with BM grafts and PB grafts.
•Immune reconstitution was similar with BM grafts and PB grafts
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas